Special Issue

Personalizing Head and Neck Cancer Care

Message from the Guest Editors

An important development in head and neck cancer research lies in personalizing cancer care. Patients with head and neck cancer are at high risk of physical, functional, psychosocial deterioration and malnutrition. They are often sarcopenic, and are generally frailer than patients with other solid malignancies. Identifying frail patients suitable for complex treatments or requiring treatment adaptation is paramount. Prediction models and intervention trials aid us in shared decision-making and individualizing treatment. Shared decision-making models are rising in prominence and enable patients to play an active role in shaping their treatment plans. Advances in personalized treatment strategies include targeted therapies, immunotherapy, and adaptive radiation techniques, as well as prehabilitation programs addressing nutrition, physical exercise, and psychosocial interventions. Lastly, innovations in monitoring head and neck cancer help to personalize follow-up. Developments include tumor mutational burden and circulating tumor DNA, as well as the use of telecommunication and telemedicine.

Guest Editors

Dr. Inge Wegner

Department of Otorhinolaryngology—Head and Neck Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Dr. G. B. Halmos

Department of Otorhinolaryngology—Head and Neck Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Deadline for manuscript submissions

17 July 2026



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/252657

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

